公开(公告)号：US10457735B2

公开(公告)日：2019-10-29

申请号：US15538419

申请日：2016-01-08

Applicant: BIONTECH AG ,  GENMAB A/S

Inventor： Ugur Sahin ,  Friederike Gieseke ,  Isil Altintas ,  David Satijn ,  Paul Parren

IPC: C07K16/28

Abstract: The present invention relates to binding agents binding to receptors of the TNF superfamily, in particular binding agents binding to at least two different receptors of the TNF superfamily, as well as to their use in medicine. The present invention further relates to nucleic acid molecules encoding such binding agents, to cells comprising such nucleic acid molecules and to pharmaceutical compositions and kits.

公开(公告)号：US20190169311A1

公开(公告)日：2019-06-06

申请号：US15998816

申请日：2018-08-16

Applicant: Genmab A/S

Inventor： Sandra Verploegen ,  David P.E. Satijn ,  Rene M.A. Hoet ,  Paul Parren ,  Jan Van De Winkel ,  Vibeke Miller Breinholt ,  Eva Ehrnrooth ,  Ole Baadsgaard ,  Tom Vink ,  Willem Karel Bleeker ,  Mischa Houtkamp ,  Maroeska Oudshoorn ,  Rob N. De Jong

IPC: C07K16/36 ,  A61K39/395

Abstract: Isolated human monoclonal antibodies which bind to human TF and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies, and therapeutic and diagnostic methods for using the antibodies.

公开(公告)号：US20180319888A1

公开(公告)日：2018-11-08

申请号：US15977725

申请日：2018-05-11

Applicant: Genmab A/S

Inventor： Aran Frank Labrijn ,  Stefan Loverix ,  Paul Parren ,  Jan Van De Winkel ,  Janine Schuurman ,  Ignace Lasters

IPC: C07K16/28 ,  C07K16/00 ,  A61K47/68 ,  A61K51/10 ,  A61K39/395

CPC classification number: C07K16/2863 ,  A61K39/3955 ,  A61K47/6849 ,  A61K51/103 ,  A61K2039/505 ,  C07K16/00 ,  C07K2317/21 ,  C07K2317/52 ,  C07K2317/524 ,  C07K2317/526 ,  C07K2317/53 ,  C07K2317/76

Abstract: The present invention relates to positions in the constant region of antibodies, in particular the CH3 region of IgG4, which affect the strength of CH3-CH3 interactions. Mutations that either stabilize or destabilize this interaction are disclosed.

公开(公告)号：US20180298106A1

公开(公告)日：2018-10-18

申请号：US15909540

申请日：2018-03-01

Applicant: GENMAB A/S

Inventor： Michel DE WEERS ,  Tim WALSETH ,  Jan VAN DE WINKEL ,  Tom VINK ,  Paul PARREN

IPC: C07K16/28 ,  G01N33/573 ,  A61K45/06 ,  A61K39/395

Abstract: Isolated monoclonal antibodies which bind to human CD38 and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies.

公开(公告)号：US20180201693A1

公开(公告)日：2018-07-19

申请号：US15742803

申请日：2016-07-01

Applicant: GENMAB A/S

Inventor： Richard G. HIBBERT ,  Aran F. LABRIJN ,  Arnout F. GERRITSEN ,  Janine SCHUURMAN ,  Paul PARREN

IPC: C07K16/46

CPC classification number: C07K16/468 ,  C07K16/2863 ,  C07K16/2887 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/515 ,  C07K2317/526 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/92 ,  C07K2317/94

Abstract: Bispecific and multispecific antibodies having differentially modified light chains, that allows for isolation of the bispecific or multispecific antibodies based on a differential affinity towards an affinity reagent.

公开(公告)号：US20170369594A1

公开(公告)日：2017-12-28

申请号：US15599395

申请日：2017-05-18

Applicant: GENMAB A/S

Inventor： Joost J. NEIJSSEN ,  Joyce I. MEESTERS ,  Bart DE GOEIJ ,  Aran Frank LABRIJN ,  Paul PARREN ,  Janine SCHUURMAN

IPC: C07K16/46 ,  A61K39/395 ,  C07K1/113 ,  C07K16/10 ,  C07K16/28 ,  A61K47/68 ,  C07K16/32 ,  A61K39/00

Abstract: Bispecific antibodies which comprise one antigen-binding region binding to an epitope of human epidermal growth factor receptor 2 (HER2) and one antigen-binding region binding to human CD3, and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and methods for preparing and using the antibodies are also disclosed.

公开(公告)号：US20170327597A1

公开(公告)日：2017-11-16

申请号：US15536143

申请日：2015-12-18

Applicant: GENMAB A/S

Inventor： Aran F. LABRIJN ,  Joyce I. MEESTERS ,  Janine SCHUURMAN ,  Paul PARREN ,  Anthony ARMSTRONG ,  Matthew BUNCE ,  Mark CHIU ,  Thomas NESSPOR ,  Adam ZWOLAK

IPC: C07K16/46 ,  C07K16/40 ,  A61K49/00 ,  C07K16/28

CPC classification number: C07K16/462 ,  A61K49/0008 ,  C07K16/00 ,  C07K16/2809 ,  C07K16/32 ,  C07K16/40 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/526 ,  C07K2317/64 ,  C07K2317/73

Abstract: Novel rodent bispecific heterodimeric proteins, such as rodent bispecific antibodies, in vitro method for producing such, and uses thereof.

公开(公告)号：US20170240640A1

公开(公告)日：2017-08-24

申请号：US15420824

申请日：2017-01-31

Applicant: GENMAB A/S

Inventor： Janine SCHUURMAN ,  Catharina Emanuele Gerarda HAVENITH ,  Paul PARREN ,  Jan G. J. VAN DE WINKEL ,  Denise Leah WILLIAMS ,  Jørgen PETERSEN ,  Ole BAADSGAARD

IPC: C07K16/28 ,  G01N33/569 ,  C07K16/42 ,  G01N33/68 ,  A61K45/06 ,  A61K39/395

Abstract: Isolated human monoclonal antibodies which bind to and inhibit human CD25, and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced by a hybridoma, a transfectoma or in a nonhuman transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, nonhuman transgenic animals, hybridomas and transfectomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.

公开(公告)号：US20160067349A1

公开(公告)日：2016-03-10

申请号：US14854613

申请日：2015-09-15

Applicant: GENMAB A/S

Inventor： David SATIJN ,  Sandra VERPLOEGEN ,  Wim BLEEKER ,  Steen LISBY ,  Jan VAN DE WINKEL ,  Patrick VAN BERKEL ,  Paul PARREN

IPC: A61K47/48 ,  C07K16/30 ,  A61K45/06

CPC classification number: A61K47/48561 ,  A61K45/06 ,  A61K47/6817 ,  A61K47/6849 ,  C07K16/30 ,  C07K16/36 ,  C07K2317/21 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/92

Abstract: Antibody drug conjugates against tissue factor. Also disclosed are pharmaceutical compositions comprising the antibodies and antibody drug conjugates, and therapies and diagnostic methods for using the antibodies and antibody drug conjugates.

Abstract translation: 针对组织因子的抗体药物偶联物。 还公开了包含抗体和抗体药物共轭物的药物组合物，以及使用抗体和抗体药物偶联物的治疗和诊断方法。

公开(公告)号：US20150376282A1

公开(公告)日：2015-12-31

申请号：US14739768

申请日：2015-06-15

Applicant: Genmab A/S

Inventor： Aran Frank Labrijn ,  Stefan Loverix ,  Paul Parren ,  Jan Van De Winkel ,  Janine Schuurman ,  Ignace Laster

IPC: C07K16/28 ,  A61K47/48 ,  A61K51/10 ,  A61K39/395

CPC classification number: C07K16/2863 ,  A61K39/3955 ,  A61K47/6849 ,  A61K51/103 ,  A61K2039/505 ,  C07K16/00 ,  C07K2317/21 ,  C07K2317/52 ,  C07K2317/524 ,  C07K2317/526 ,  C07K2317/53 ,  C07K2317/76

Abstract: The present invention relates to positions in the constant region of antibodies, in particular the CH3 region of IgG4, which affect the strength of CH3-CH3 interactions. Mutations that either stabilize or destabilize this interaction are disclosed.

Abstract translation: 本发明涉及抗体的恒定区，特别是IgG4的CH3区的位置，其影响了CH3-CH3相互作用的强度。 公开了稳定或不稳定这种相互作用的突变。